---
figid: PMC7598617__biomolecules-10-01361-g004
figlink: pmc/articles/PMC7598617/figure/biomolecules-10-01361-f004/
number: Figure 4
caption: 'Potential therapeutic strategies modulating Th17/IL-17A response in damaged
  peritoneum: briefly, Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonists
  inhibit Th17 response via signal transducer and activator of transcription 3 (STAT3)
  blockade and downregulation of retinoid related orphan receptor γt (RORγt) and IL-6
  but promote Treg response by the induction of anti-inflammatory cytokine IL-10.
  mTOR inhibition, via the hypoxia-induced factor-1 (HIF-1) pathway, downregulates
  Th17 response. Vitamin D receptor (VDR) activation and inhibition of the COX-2/PGE2
  axis also target Th17 differentiation by decreased STAT3 activation and RORγt expression.
  Ala-Gln supplemented in PDF reduces IL-17A and IL-6 production. Other common drugs
  used in PD patients such as renin-angiotensin system (RAS) blockers, including angiotensin
  converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and
  statins may also modulate Th17 response. All these drugs also present other beneficial
  effects in the damaged peritoneum. Green arrows: activation, red arrows: inhibition.'
pmcid: PMC7598617
papertitle: IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis.
reftext: Vanessa Marchant, et al. Biomolecules. 2020 Oct;10(10):1361.
pmc_ranked_result_index: '60083'
pathway_score: 0.9672074
filename: biomolecules-10-01361-g004.jpg
figtitle: IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7598617__biomolecules-10-01361-g004.html
  '@type': Dataset
  description: 'Potential therapeutic strategies modulating Th17/IL-17A response in
    damaged peritoneum: briefly, Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ)
    agonists inhibit Th17 response via signal transducer and activator of transcription
    3 (STAT3) blockade and downregulation of retinoid related orphan receptor γt (RORγt)
    and IL-6 but promote Treg response by the induction of anti-inflammatory cytokine
    IL-10. mTOR inhibition, via the hypoxia-induced factor-1 (HIF-1) pathway, downregulates
    Th17 response. Vitamin D receptor (VDR) activation and inhibition of the COX-2/PGE2
    axis also target Th17 differentiation by decreased STAT3 activation and RORγt
    expression. Ala-Gln supplemented in PDF reduces IL-17A and IL-6 production. Other
    common drugs used in PD patients such as renin-angiotensin system (RAS) blockers,
    including angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor
    blockers (ARBs), and statins may also modulate Th17 response. All these drugs
    also present other beneficial effects in the damaged peritoneum. Green arrows:
    activation, red arrows: inhibition.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FOXP3
  - SETD2
  - MTOR
  - IL10
  - STAT3
  - VDR
  - IL6
  - VIT
  - HRAS
  - KRAS
  - NRAS
  - IL17RA
  - AQP1
  - TGFB1
  - TGFB2
  - TGFB3
  - NLRP3
  - PGE2
  - Ala-Gln
  - Statins
genes:
- word: FoxP3
  symbol: FOXP3
  source: hgnc_symbol
  hgnc_symbol: FOXP3
  entrez: '50943'
- word: HIF-1
  symbol: HIF-1
  source: hgnc_alias_symbol
  hgnc_symbol: SETD2
  entrez: '29072'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: IL-10
  symbol: IL-10
  source: hgnc_alias_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: VDR
  symbol: VDR
  source: hgnc_symbol
  hgnc_symbol: VDR
  entrez: '7421'
- word: (IL-6
  symbol: IL6
  source: hgnc_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: VDR
  symbol: VDR
  source: hgnc_symbol
  hgnc_symbol: VDR
  entrez: '7421'
- word: Vit
  symbol: VIT
  source: hgnc_symbol
  hgnc_symbol: VIT
  entrez: '5212'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: IL-17R
  symbol: IL17R
  source: hgnc_prev_symbol
  hgnc_symbol: IL17RA
  entrez: '23765'
- word: AQP-1
  symbol: AQP1
  source: hgnc_symbol
  hgnc_symbol: AQP1
  entrez: '358'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: TGF-B
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: NLRP3
  symbol: NLRP3
  source: hgnc_symbol
  hgnc_symbol: NLRP3
  entrez: '114548'
chemicals:
- word: PGE2
  source: MESH
  identifier: D015232
- word: Ala-Gln
  source: MESH
  identifier: C054122
- word: Statins
  source: MESH
  identifier: D019821
diseases: []
---
